Mimicry of High-Density Lipoprotein: Functional Peptide鈥揕ipid Nanoparticles Based on Multivalent Peptide Constructs
详细信息 查看全文
- 作者：Yannan Zhao ; Tomohiro Imura ; Luke J. Leman ; Linda K. Curtiss ; Bruce E. Maryanoff ; M. Reza Ghadiri
- 刊名：Journal of the American Chemical Society
- 出版年：2013
- 出版时间：September 11, 2013
- 年：2013
- 卷：135
- 期：36
- 页码：13414-13424
- 全文大小：659K
- 年卷期：v.135,no.36(September 11, 2013)
- ISSN：1520-5126
文摘
We describe an approach for engineering peptide鈥搇ipid nanoparticles that function similarly to high-density lipoprotein (HDL). Branched, multivalent constructs, bearing multiple 23- or 16-amino-acid peptides, were designed, synthesized, and combined with phospholipids to produce nanometer-scale discoidal HDL-like particles. A variety of biophysical techniques were employed to characterize the constructs, including size exclusion chromatography, analytical ultracentrifuge sedimentation, circular dichroism, transmission electron microscopy, and fluorescence spectroscopy. The nanoparticles functioned in vitro (human and mouse plasma) and in vivo (mice) to rapidly remodel large native HDLs into small lipid-poor HDL particles, which are key acceptors of cholesterol in reverse cholesterol transport. Fluorescent labeling studies showed that the constituents of the nanoparticles readily distributed into native HDLs, such that the peptide constructs coexisted with apolipoprotein A-I (apoA-I), the main structural protein in HDLs. Importantly, nanolipid particles containing multivalent peptides promoted efficient cellular cholesterol efflux and were functionally superior to those derived from monomeric apoA-I mimetic peptides. The multivalent peptide鈥搇ipid nanoparticles were also remarkably stable toward enzymatic digestion in vitro and displayed long half-lives and desirable pharmacokinetic profiles in mice, providing a real practical advantage over previously studied linear or tandem helical peptides. Encouragingly, a two-week exploratory efficacy study in a widely used animal model for atherosclerosis research (LDLr-null mice) using nanoparticles constructed from a trimeric peptide demonstrated an exceptional 50% reduction in the plasma total cholesterol levels compared to the control group. Altogether, the studies reported here point to an attractive avenue for designing synthetic, HDL-like nanoparticles, with potential for treating atherosclerosis.